News

Deal Announcements

Cylene Pharma Secures $12 Million Venture Capital

Tuesday, September 28, 2010 5:36:00 AM PDT | VentureDeal Staff
San Diego, California  --  Small molecule company Cylene Pharmaceuticals has secured $12 million in new institutional venture capital financing.

Cylene is developing drugs to treat life-threatening diseases and is focusing on cancer related conditions.

Investors in the round included Sanderling Ventures, HBM BioVentures, Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. Ltd. and the Morningside Group

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1